| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Diagnostics and Genetics |
1 Dipartimento Materno Infantile e Tecnologie Biomediche, University of Brescia, viale Europa 11, 25123 Brescia, Italy.
aAuthor for correspondence. Fax 39-030-307-251; e-mail arosio{at}med.unibs.it.
Background: Hereditary hemochromatosis is a recessive disorder characterized by iron accumulation in parenchymal cells, followed by organ damage and failure. The disorder is mainly attributable to the C282Y and H63D mutations in the HFE gene, but additional mutations in the HFE, transferrin receptor 2 (TfR2), and hepcidin genes have been reported. The copresence of mutations in different genes may explain the phenotypic heterogeneity of the disorder and its variable penetrance.
Methods: We used denaturing HPLC (DHPLC) for rapid DNA scanning of the HFE (exons 2, 3, and 4), hepcidin, and TfR2 (exons 2, 4 and 6) genes in a cohort of 657 individuals with altered indicators of iron status.
Results: DHPLC identification of C282Y and H63D HFE alleles was in perfect agreement with the restriction endonuclease assay. Fourteen DNA samples were heterozygous for the HFE S65C mutation. In addition, we found novel mutations: two in HFE (R66C in exon 2 and R224G in exon 4), one in the hepcidin gene (G71D), and one in TfR2 (V22I), plus several intronic or silent substitutions. Six of the seven individuals with hepcidin or TfR2 coding mutations carried also HFE C282Y or S65C mutations.
Conclusion: DHPLC is an efficient method for mutational screening for the genes involved in hereditary hemochromatosis and for the study of their copresence.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  R. S. Ajioka, J. D. Phillips, R. B. Weiss, D. M. Dunn, M. W. Smit, S. C. Proll, M. G. Katze, and J. P. Kushner Down-regulation of hepcidin in porphyria cutanea tarda Blood, December 1, 2008; 112(12): 4723 - 4728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Biasiotto, C. Camaschella, G. L. Forni, A. Polotti, G. Zecchina, and P. Arosio New TFR2 mutations in young Italian patients with hemochromatosis Haematologica, February 1, 2008; 93(2): 309 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cunat, M. Giansily-Blaizot, M. Bismuth, F. Blanc, O. Dereure, D. Larrey, A. L. Quellec, P. Pouderoux, C. Rose, I. Raingeard, et al. Global Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders Clin. Chem., December 1, 2007; 53(12): 2060 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Johnson, J. Chen, N. Murchison, F. A. Green, and C. A. Enns Transferrin Receptor 2: Evidence for Ligand-induced Stabilization and Redirection to a Recycling Pathway Mol. Biol. Cell, March 1, 2007; 18(3): 743 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Drake, E. H. Morgan, C. E. Herbison, R. Delima, R. M. Graham, A. C. G. Chua, P. J. Leedman, R. E. Fleming, B. R. Bacon, J. K. Olynyk, et al. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3 Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G323 - G328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Truksa, H. Peng, P. Lee, and E. Beutler Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6 PNAS, July 5, 2006; 103(27): 10289 - 10293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches Clin. Chem., June 1, 2006; 52(6): 950 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Crepin, P. Pigny, F. Escande, C. C. Bauters, A. Calender, S. Lefevre, M.-P. Buisine, N. Porchet, and M.-F. Odou Evaluation of denaturing high performance liquid chromatography for the mutational analysis of the MEN1 gene. J. Mol. Endocrinol., April 1, 2006; 36(2): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nemeth, G. C. Preza, C.-L. Jung, J. Kaplan, A. J. Waring, and T. Ganz The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study Blood, January 1, 2006; 107(1): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Camaschella Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders Blood, December 1, 2005; 106(12): 3710 - 3717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K J H Robson, A T Merryweather-Clarke, E Cadet, V Viprakasit, M G Zaahl, J J Pointon, D J Weatherall, and J Rochette Recent advances in understanding haemochromatosis: a transition state J. Med. Genet., October 1, 2004; 41(10): 721 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Le Gac, V. Scotet, C. Ka, I. Gourlaouen, L. Bryckaert, S. Jacolot, C. Mura, and C. Ferec The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype Hum. Mol. Genet., September 1, 2004; 13(17): 1913 - 1918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lanzara, A. Roetto, F. Daraio, S. Rivard, R. Ficarella, H. Simard, T. M. Cox, M. Cazzola, A. Piperno, A.-P. Gimenez-Roqueplo, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis Blood, June 1, 2004; 103(11): 4317 - 4321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Roetto, F. Daraio, P. Porporato, R. Caruso, T. M. Cox, M. Cazzola, P. Gasparini, A. Piperno, and C. Camaschella Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R) Blood, March 15, 2004; 103(6): 2407 - 2409. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
